Raras
Buscar doenças, sintomas, genes...
Sarcoma de tecidos moles
ORPHA:3394DOENÇA RARA

Um câncer que surge do tecido muscular, da gordura, dos vasos sanguíneos, do tecido fibroso ou de outros tecidos de suporte, com exceção dos ossos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um câncer que surge do tecido muscular, da gordura, dos vasos sanguíneos, do tecido fibroso ou de outros tecidos de suporte, com exceção dos ossos.

Pesquisas ativas
16 ensaios
2973 total registrados no ClinicalTrials.gov
Publicações científicas
11.361 artigos
Último publicado: 2026 Apr 17

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
30.0
Europe
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
10 sintomas
🩸
Sangue
8 sintomas
🧬
Pele e cabelo
7 sintomas
🧠
Neurológico
7 sintomas
🫘
Rins
6 sintomas
📏
Crescimento
4 sintomas

+ 46 sintomas em outras categorias

Características mais comuns

Anormalidade do fígado
Lipossarcoma mixoide
Pele espessada
Linfadenopatia mediastinal
Caquexia
Neoplasia ovariana
103sintomas
Sem dados (103)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 103 características clínicas mais associadas, ordenadas por frequência.

Anormalidade do fígadoAbnormality of the liver
Lipossarcoma mixoideMyxoid liposarcoma
Pele espessadaThickened skin
Linfadenopatia mediastinalMediastinal lymphadenopathy
CaquexiaCachexia

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico11.361PubMed
Últimos 10 anos200publicações
Pico2026166 papers
Linha do tempo
2026Hoje · 2026🧪 1983Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

41 genes identificados com associação a esta condição.

FOXO1Forkhead box protein O1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress (PubMed:10358076, PubMed:12228231, PubMed:15220471, PubMed:15890677, PubMed:18356527, PubMed:19221179, PubMed:20543840, PubMed:21245099). Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3' (PubMed:10358076). Activity suppressed by insu

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genesRegulation of gene expression in beta cellsFOXO-mediated transcription of cell death genesFOXO-mediated transcription of cell cycle genesRegulation of localization of FOXO transcription factors
MECANISMO DE DOENÇA

Rhabdomyosarcoma 2

A form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchymal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
110.7 TPM
Nervo tibial
109.3 TPM
Útero
73.4 TPM
Músculo esquelético
66.8 TPM
Fallopian Tube
65.4 TPM
OUTRAS DOENÇAS (1)
alveolar rhabdomyosarcoma
HGNC:3819UniProt:Q12778
NTRK3NT-3 growth factor receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Receptor tyrosine kinase involved in nervous system and probably heart development. Upon binding of its ligand NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the phosphatidylinositol 3-kinase/AKT and the MAPK pathways, that control cell survival and differentiation

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (4)
NTF3 activates NTRK3 signalingSignaling by NTRK3 (TRKC)NTRK3 as a dependence receptorReceptor-type tyrosine-protein phosphatases
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
32.5 TPM
Artéria coronária
22.1 TPM
Aorta
21.6 TPM
Cerebelo
15.8 TPM
Cérebro - Hemisfério cerebelar
13.9 TPM
OUTRAS DOENÇAS (3)
congenital mesoblastic nephromadifferentiated thyroid carcinomafibrosarcoma
HGNC:8033UniProt:Q16288
FLI1Friend leukemia integration 1 transcription factorCandidate gene tested inAltamente restrito
FUNÇÃO

Sequence-specific transcriptional activator (PubMed:24100448, PubMed:26316623, PubMed:28255014). Recognizes the DNA sequence 5'-C[CA]GGAAGT-3'

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Transcriptional regulation of granulopoiesis
MECANISMO DE DOENÇA

Ewing sarcoma

A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
90.1 TPM
Pulmão
43.0 TPM
Tecido adiposo
38.9 TPM
Linfócitos
37.4 TPM
Sangue
33.9 TPM
OUTRAS DOENÇAS (7)
bleeding disorder, platelet-type, 21Jacobsen syndromeParis-Trousseau thrombocytopeniaisolated delta-storage pool disease
HGNC:3749UniProt:Q01543
CDK4Cyclin-dependent kinase 4Candidate gene tested inRestrito
FUNÇÃO

Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are ma

LOCALIZAÇÃO

CytoplasmNucleusNucleus membrane

VIAS BIOLÓGICAS (7)
Cyclin D associated events in G1Transcriptional regulation by RUNX2Ubiquitin-dependent degradation of Cyclin DMeiotic recombinationRMTs methylate histone arginines
MECANISMO DE DOENÇA

Melanoma, cutaneous malignant 3

A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but may also involve other sites.

OUTRAS DOENÇAS (4)
familial melanomadedifferentiated liposarcomawell-differentiated liposarcomamelanoma, cutaneous malignant, susceptibility to, 3
HGNC:1773UniProt:P11802
ETV6Transcription factor ETV6Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Plays a role in hematopoiesis and malignant transformation

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Signaling by FLT3 fusion proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
45.0 TPM
Glândula salivar
42.7 TPM
Skin Sun Exposed Lower leg
35.5 TPM
Linfócitos
30.0 TPM
Aorta
29.4 TPM
OUTRAS DOENÇAS (9)
acute myeloid leukemiathrombocytopenia 5B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)obsolete autosomal thrombocytopenia with normal platelets
HGNC:3495UniProt:P41212
SMARCA5SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5Candidate gene tested inAltamente restrito
FUNÇÃO

ATPase that possesses intrinsic ATP-dependent nucleosome-remodeling activity (PubMed:12972596, PubMed:28801535). Catalytic subunit of ISWI chromatin-remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair; this may require intact histone H4 tails (PubMed:10880450, PubMed:12198550, PubMed:12434153, PubMed:12972596, PubMed:23911928, PubMed:28801535). Within the ISWI chroma

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (4)
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaksDeposition of new CENPA-containing nucleosomes at the centromereB-WICH complex positively regulates rRNA expressionNoRC negatively regulates rRNA expression
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
74.8 TPM
Testículo
56.6 TPM
Fibroblastos
54.9 TPM
Ovário
42.8 TPM
Nervo tibial
42.7 TPM
OUTRAS DOENÇAS (1)
extraskeletal Ewing sarcoma
HGNC:11101UniProt:O60264
TFGProtein TFGCandidate gene tested inModerado
FUNÇÃO

Plays a role in the normal dynamic function of the endoplasmic reticulum (ER) and its associated microtubules (PubMed:23479643, PubMed:27813252). Required for secretory cargo traffic from the endoplasmic reticulum to the Golgi apparatus (PubMed:21478858)

LOCALIZAÇÃO

Endoplasmic reticulum

VIAS BIOLÓGICAS (1)
COPII-mediated vesicle transport
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
86.6 TPM
Linfócitos
61.6 TPM
Tireoide
60.1 TPM
Nervo tibial
55.3 TPM
Aorta
53.8 TPM
OUTRAS DOENÇAS (5)
hereditary motor and sensory neuropathy, Okinawa typehereditary spastic paraplegia 57autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutationdifferentiated thyroid carcinoma
HGNC:11758UniProt:Q92734
HTRA1Serine protease HTRA1Candidate gene tested inTolerante
FUNÇÃO

Serine protease with a variety of targets, including extracellular matrix proteins such as fibronectin. HTRA1-generated fibronectin fragments further induce synovial cells to up-regulate MMP1 and MMP3 production. May also degrade proteoglycans, such as aggrecan, decorin and fibromodulin. Through cleavage of proteoglycans, may release soluble FGF-glycosaminoglycan complexes that promote the range and intensity of FGF signals in the extracellular space. Regulates the availability of insulin-like g

LOCALIZAÇÃO

Cell membraneSecretedCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Degradation of the extracellular matrix
EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
810.7 TPM
Ovário
602.0 TPM
Cervix Ectocervix
551.9 TPM
Fibroblastos
518.4 TPM
Artéria tibial
426.1 TPM
OUTRAS DOENÇAS (5)
cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2CARASIL syndromemalignant perineuriomaHTRA1-related autosomal dominant cerebral small vessel disease
HGNC:9476UniProt:Q92743
SMARCA4SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4Candidate gene tested inAltamente restrito
FUNÇÃO

ATPase involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:15075294, PubMed:29374058, PubMed:30339381, PubMed:32459350). Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter ac

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
Formation of the beta-catenin:TCF transactivating complexNegative Regulation of CDH1 Gene TranscriptionRUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not knownRMTs methylate histone argininesFormation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
MECANISMO DE DOENÇA

Rhabdoid tumor predisposition syndrome 2

A familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
81.7 TPM
Cérebro - Hemisfério cerebelar
65.7 TPM
Cerebelo
62.6 TPM
Linfócitos
61.0 TPM
Esôfago - Mucosa
57.8 TPM
OUTRAS DOENÇAS (7)
intellectual disability, autosomal dominant 16otosclerosis 12Coffin-Siris syndromeovarian small cell carcinoma
HGNC:11100UniProt:P51532
HMGA2High mobility group protein HMGI-CCandidate gene tested inModerado
FUNÇÃO

Functions as a transcriptional regulator. Functions in cell cycle regulation through CCNA2. Plays an important role in chromosome condensation during the meiotic G2/M transition of spermatocytes. Plays a role in postnatal myogenesis, is involved in satellite cell activation (By similarity). Positively regulates IGF2 expression through PLAG1 and in a PLAG1-independent manner (PubMed:28796236)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Formation of Senescence-Associated Heterochromatin Foci (SAHF)
MECANISMO DE DOENÇA

Silver-Russell syndrome 5

A form of Silver-Russell syndrome, a clinically heterogeneous condition characterized by severe intrauterine growth retardation, poor postnatal growth, craniofacial features such as a triangular shaped face and a broad forehead, body asymmetry, and a variety of minor malformations. The phenotypic expression changes during childhood and adolescence, with the facial features and asymmetry usually becoming more subtle with age. SRS5 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fibroblastos
14.4 TPM
Testículo
1.4 TPM
Nervo tibial
1.0 TPM
Cólon transverso
0.6 TPM
Intestino delgado
0.3 TPM
OUTRAS DOENÇAS (6)
Silver-Russell syndrome 512q14 microdeletion syndromeobsolete Silver-Russell syndrome due to a point mutationdedifferentiated liposarcoma
HGNC:5009UniProt:P52926
MDM2E3 ubiquitin-protein ligase Mdm2Candidate gene tested inAltamente restrito
FUNÇÃO

E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome (PubMed:29681526). Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its

LOCALIZAÇÃO

Nucleus, nucleoplasmCytoplasmNucleus, nucleolusNucleus

VIAS BIOLÓGICAS (6)
Regulation of TP53 DegradationAKT phosphorylates targets in the cytosolDegradation of CDH1NPAS4 regulates expression of target genesConstitutive Signaling by AKT1 E17K in Cancer
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
32.5 TPM
Linfócitos
29.9 TPM
Pulmão
18.3 TPM
Tecido adiposo
17.9 TPM
Nervo tibial
16.0 TPM
OUTRAS DOENÇAS (5)
lessel-kubisch syndromeLi-Fraumeni syndromededifferentiated liposarcomawell-differentiated liposarcoma
HGNC:6973UniProt:Q00987
WT1Wilms tumor proteinCandidate gene tested inAltamente restrito
FUNÇÃO

Transcription factor that plays an important role in cellular development and cell survival (PubMed:7862533). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:17716689, PubMed:25258363, PubMed:7862533). Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may a

LOCALIZAÇÃO

NucleusNucleus, nucleolusCytoplasmNucleus speckleNucleus, nucleoplasm

VIAS BIOLÓGICAS (3)
Nephron developmentNegative Regulation of CDH1 Gene TranscriptionTranscriptional regulation of testis differentiation
MECANISMO DE DOENÇA

Frasier syndrome

Characterized by a slowly progressing nephropathy leading to renal failure in adolescence or early adulthood, male pseudohermaphroditism, and no Wilms tumor. As for histological findings of the kidneys, focal glomerular sclerosis is often observed. There is phenotypic overlap with Denys-Drash syndrome. Inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Útero
109.7 TPM
Fallopian Tube
75.2 TPM
Ovário
65.2 TPM
Testículo
40.5 TPM
Adipose Visceral Omentum
30.0 TPM
OUTRAS DOENÇAS (12)
Wilms tumor 1nephrotic syndrome, type 4Meacham syndromemalignant mesothelioma
HGNC:12796UniProt:P19544
PDGFBPlatelet-derived growth factor subunit BCandidate gene tested inAltamente restrito
FUNÇÃO

Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin (PubMed:26599395). Required for normal proliferation and recruitment of pericytes and vascular smooth muscle cells in the central nervous system, skin, lung, heart and placenta. Required for normal blood vessel development, and for normal development of kidney glomeruli. Plays an important role in wound

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (8)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingConstitutive Signaling by Aberrant PI3K in CancerDownstream signal transductionRAF/MAP kinase cascade
MECANISMO DE DOENÇA

Basal ganglia calcification, idiopathic, 5

A form of basal ganglia calcification, an autosomal dominant condition characterized by symmetric calcification in the basal ganglia and other brain regions. Affected individuals can either be asymptomatic or show a wide spectrum of neuropsychiatric symptoms, including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, seizures, and chronic headache. Serum levels of calcium, phosphate, alkaline phosphatase and parathyroid hormone are normal. The neuropathological hallmark of the disease is vascular and pericapillary calcification, mainly of calcium phosphate, in the affected brain areas.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
49.1 TPM
Pulmão
45.8 TPM
Adipose Visceral Omentum
43.1 TPM
Mama
34.1 TPM
Tireoide
30.5 TPM
OUTRAS DOENÇAS (6)
familial meningiomabasal ganglia calcification, idiopathic, 5familial multiple meningiomameningioma
HGNC:8800UniProt:P01127
COL1A1Collagen alpha-1(I) chainCandidate gene tested inAltamente restrito
FUNÇÃO

Type I collagen is a member of group I collagen (fibrillar forming collagen)

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (10)
MET activates PTK2 signalingDevelopmental Lineage of Pancreatic Ductal CellsAssembly of collagen fibrils and other multimeric structuresECM proteoglycansFibronectin matrix formation
MECANISMO DE DOENÇA

Caffey disease

An autosomal dominant disorder characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age.

OUTRAS DOENÇAS (13)
Ehlers-Danlos syndrome type 7Aosteogenesis imperfecta type 3osteogenesis imperfecta type 4osteogenesis imperfecta type 1
HGNC:2197UniProt:P02452
DDIT3DDIT3 upstream open reading frame proteinCandidate gene tested inTolerante
FUNÇÃO

Product of the upstream open reading frame (uORF) of DDIT3/CHOP that is specifically produced in absence of stress, thereby preventing translation of downstream stress effector DDIT3/CHOP

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (5)
FOXO-mediated transcription of cell death genesResponse of EIF2AK1 (HRI) to heme deficiencyResponse of EIF2AK4 (GCN2) to amino acid deficiencyATF6 (ATF6-alpha) activates chaperone genesATF4 activates genes in response to endoplasmic reticulum stress
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
128.4 TPM
Pituitária
111.4 TPM
Artéria tibial
84.1 TPM
Bladder
81.2 TPM
Rim - Medula
80.6 TPM
OUTRAS DOENÇAS (1)
myxoid/round cell liposarcoma
HGNC:2726UniProt:P0DPQ6
TCF12Transcription factor 12Candidate gene tested inTolerante
FUNÇÃO

Transcriptional regulator. Involved in the initiation of neuronal differentiation. Activates transcription by binding to the E box (5'-CANNTG-3') (By similarity). May be involved in the functional network that regulates the development of the GnRH axis (PubMed:32620954)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (5)
Negative Regulation of CDH1 Gene TranscriptionRUNX1 regulates transcription of genes involved in differentiation of HSCsNGF-stimulated transcriptionMyogenesisTGFBR3 expression
MECANISMO DE DOENÇA

Craniosynostosis 3

A primary abnormality of skull growth involving premature fusion of one or more cranial sutures. The growth velocity of the skull often cannot match that of the developing brain resulting in an abnormal head shape and, in some cases, increased intracranial pressure, which must be treated promptly to avoid permanent neurodevelopmental disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
39.7 TPM
Cervix Ectocervix
38.1 TPM
Fibroblastos
37.1 TPM
Útero
32.3 TPM
Nervo tibial
28.4 TPM
OUTRAS DOENÇAS (4)
hypogonadotropic hypogonadism 26 with or without anosmiaTCF12-related craniosynostosisextraskeletal myxoid chondrosarcomaobsolete isolated brachycephaly
HGNC:11623UniProt:Q99081
YWHAE14-3-3 protein epsilonCandidate gene tested inAltamente restrito
FUNÇÃO

Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:21189250). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:35343654). Binding generally results in the modulation of the activity of the binding partner (By similarity). Positively regulates phosphorylated protein HSF1 nuclear export to the cytoplasm (PubMed:12917326). Plays a positive role in the antiviral si

LOCALIZAÇÃO

NucleusCytoplasmMelanosome

VIAS BIOLÓGICAS (10)
Recruitment of mitotic centrosome proteins and complexesLoss of proteins required for interphase microtubule organization from the centrosomeLoss of Nlp from mitotic centrosomesRegulation of PLK1 Activity at G2/M TransitionAURKA Activation by TPX2
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
592.3 TPM
Brain Spinal cord cervical c-1
579.8 TPM
Brain Frontal Cortex BA9
577.0 TPM
Fibroblastos
492.8 TPM
Brain Anterior cingulate cortex BA24
483.1 TPM
OUTRAS DOENÇAS (5)
distal 17p13.3 microdeletion syndromeMiller-Dieker lissencephaly syndromechromosome 17p13.3 duplication syndromeclear cell sarcoma of kidney
HGNC:12851UniProt:P62258
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
CREB3L2Cyclic AMP-responsive element-binding protein 3-like protein 2Candidate gene tested inRestrito
FUNÇÃO

Transcription factor involved in unfolded protein response (UPR). In the absence of endoplasmic reticulum (ER) stress, inserted into ER membranes, with N-terminal DNA-binding and transcription activation domains oriented toward the cytosolic face of the membrane. In response to ER stress, transported to the Golgi, where it is cleaved in a site-specific manner by resident proteases S1P/MBTPS1 and S2P/MBTPS2. The released N-terminal cytosolic domain is translocated to the nucleus to effect transcr

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus

VIAS BIOLÓGICAS (1)
CREB3 factors activate genes
EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
77.6 TPM
Tireoide
74.0 TPM
Útero
70.8 TPM
Fibroblastos
61.7 TPM
Artéria tibial
60.9 TPM
OUTRAS DOENÇAS (1)
myxofibrosarcoma
HGNC:23720UniProt:Q70SY1
CREB3L1Cyclic AMP-responsive element-binding protein 3-like protein 1Candidate gene tested inTolerante
FUNÇÃO

Precursor of the transcription factor form (Processed cyclic AMP-responsive element-binding protein 3-like protein 1), which is embedded in the endoplasmic reticulum membrane with N-terminal DNA-binding and transcription activation domains oriented toward the cytosolic face of the membrane (PubMed:12054625, PubMed:16417584, PubMed:25310401). In response to ER stress or DNA damage, transported to the Golgi, where it is cleaved in a site-specific manner by resident proteases S1P/MBTPS1 and S2P/MBT

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus

VIAS BIOLÓGICAS (1)
CREB3 factors activate genes
MECANISMO DE DOENÇA

Osteogenesis imperfecta 16

An autosomal recessive form of osteogenesis imperfecta, a disorder of bone formation characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI16 is a severe form.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
103.5 TPM
Glândula salivar
83.5 TPM
Próstata
60.5 TPM
Estômago
54.5 TPM
Cervix Ectocervix
53.4 TPM
OUTRAS DOENÇAS (3)
osteogenesis imperfecta type 16myxofibrosarcomaosteogenesis imperfecta type 3
HGNC:18856UniProt:Q96BA8
SH3PXD2ASH3 and PX domain-containing protein 2ACandidate gene tested inAltamente restrito
FUNÇÃO

Adapter protein involved in invadopodia and podosome formation, extracellular matrix degradation and invasiveness of some cancer cells (PubMed:27789576). Binds matrix metalloproteinases (ADAMs), NADPH oxidases (NOXs) and phosphoinositides. Acts as an organizer protein that allows NOX1- or NOX3-dependent reactive oxygen species (ROS) generation and ROS localization. In association with ADAM12, mediates the neurotoxic effect of amyloid-beta peptide

LOCALIZAÇÃO

CytoplasmCell projection, podosome

VIAS BIOLÓGICAS (2)
Invadopodia formationCDC42 GTPase cycle
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
133.9 TPM
Nervo tibial
122.7 TPM
Cervix Endocervix
116.5 TPM
Útero
90.9 TPM
Fibroblastos
75.5 TPM
OUTRAS DOENÇAS (2)
malignant triton tumormalignant perineurioma
HGNC:23664UniProt:Q5TCZ1
IRX2Iroquois-class homeodomain protein IRX-2Candidate gene tested inTolerante
LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Nephron development
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula salivar
42.9 TPM
Skin Not Sun Exposed Suprapubic
40.2 TPM
Skin Sun Exposed Lower leg
34.0 TPM
Pulmão
23.8 TPM
Rim - Medula
23.6 TPM
OUTRAS DOENÇAS (1)
clear cell sarcoma of kidney
HGNC:14359UniProt:Q9BZI1
BCORBCL-6 corepressorCandidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Microphthalmia, syndromic, 2

A very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.

OUTRAS DOENÇAS (4)
microphthalmia, syndromic 2acute promyelocytic leukemiaclear cell sarcoma of kidneymicrophthalmia, Lenz type
HGNC:20893UniProt:Q6W2J9
TERTTelomerase reverse transcriptaseCandidate gene tested inRestrito
FUNÇÃO

Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-de

LOCALIZAÇÃO

Nucleus, nucleolusNucleus, nucleoplasmNucleusChromosome, telomereCytoplasmNucleus, PML body

VIAS BIOLÓGICAS (3)
Telomere Extension By TelomeraseFormation of the beta-catenin:TCF transactivating complexRegulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
2.7 TPM
Intestino delgado
0.7 TPM
Brain Caudate basal ganglia
0.6 TPM
Cólon transverso
0.5 TPM
Brain Nucleus accumbens basal ganglia
0.5 TPM
OUTRAS DOENÇAS (13)
dyskeratosis congenita, autosomal dominant 2pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1adrenal cortex carcinomaclear cell sarcoma of kidney
HGNC:11730UniProt:O14746
NUTM2ENUT family member 2ECandidate gene tested inAltamente restrito
LOCALIZAÇÃO

EXPRESSÃO TECIDUAL(Não detectado)
Testículo
0.3 TPM
Cérebro - Hemisfério cerebelar
0.1 TPM
Cerebelo
0.1 TPM
Cervix Ectocervix
0.1 TPM
Pituitária
0.1 TPM
OUTRAS DOENÇAS (1)
clear cell sarcoma of kidney
HGNC:23448UniProt:B1AL46
TFE3Transcription factor E3Candidate gene tested inAltamente restrito
FUNÇÃO

Transcription factor that acts as a master regulator of lysosomal biogenesis and immune response (PubMed:2338243, PubMed:24448649, PubMed:29146937, PubMed:30733432, PubMed:31672913, PubMed:37079666). Specifically recognizes and binds E-box sequences (5'-CANNTG-3'); efficient DNA-binding requires dimerization with itself or with another MiT/TFE family member such as TFEB or MITF (PubMed:24448649). Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the pr

LOCALIZAÇÃO

Cytoplasm, cytosolNucleusLysosome membrane

VIAS BIOLÓGICAS (1)
Transcriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Intellectual developmental disorder, X-linked, syndromic, with pigmentary mosaicism and coarse facies

A disorder characterized by severe developmental delay with impaired intellectual development and poor speech, coarse facial dysmorphisms, and Blaschkoid pigmentary mosaicism. Additional clinical features may include epilepsy, orthopedic abnormalities, hypotonia, and growth abnormalities. The disorder affects both males and females.

EXPRESSÃO TECIDUAL(Ubíquo)
Fallopian Tube
116.0 TPM
Útero
109.4 TPM
Nervo tibial
107.4 TPM
Cervix Ectocervix
103.1 TPM
Sangue
102.7 TPM
OUTRAS DOENÇAS (5)
intellectual developmental disorder, X-linked, syndromic, with pigmentary mosaicism and coarse faciesrenal cell carcinoma, Xp11-associatedalveolar soft part sarcomaMIT family translocation renal cell carcinoma
HGNC:11752UniProt:P19532
ERGTranscriptional regulator ERGCandidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (2)
Phase 3 - rapid repolarisationVoltage gated Potassium channels
MECANISMO DE DOENÇA

Ewing sarcoma

A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
48.8 TPM
Artéria tibial
28.1 TPM
Tecido adiposo
28.0 TPM
Baço
27.1 TPM
Pulmão
25.4 TPM
OUTRAS DOENÇAS (3)
lymphatic malformation 14extraskeletal Ewing sarcomaEwing sarcoma
HGNC:3446UniProt:P11308
EWSR1RNA-binding protein EWSCandidate gene tested inAltamente restrito
FUNÇÃO

Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3' (PubMed:21256132). Might normally function as a transcriptional repressor (PubMed:10767297). EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

MECANISMO DE DOENÇA

Ewing sarcoma

A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
278.5 TPM
Cérebro - Hemisfério cerebelar
273.8 TPM
Testículo
272.3 TPM
Baço
257.8 TPM
Cervix Endocervix
248.9 TPM
OUTRAS DOENÇAS (6)
Ewing sarcomaextraskeletal Ewing sarcomahistiocytoma, Angiomatoid fibrousextraskeletal myxoid chondrosarcoma
HGNC:3508UniProt:Q01844
FUSRNA-binding protein FUSCandidate gene tested inAltamente restrito
FUNÇÃO

DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response (PubMed:27731383). Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3' (PubMed:21256132). Binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing (PubMed:26124092). Also binds its own pre-mRNA and autoregulates

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
mRNA Splicing - Major PathwaymRNA PolyadenylationProcessing of Capped Intron-Containing Pre-mRNADengue Virus-Host Interactions
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
193.2 TPM
Cérebro - Hemisfério cerebelar
173.6 TPM
Cerebelo
159.0 TPM
Cervix Ectocervix
155.5 TPM
Cervix Endocervix
152.7 TPM
OUTRAS DOENÇAS (7)
tremor, hereditary essential, 4amyotrophic lateral sclerosis type 6myxoid/round cell liposarcomajuvenile amyotrophic lateral sclerosis
HGNC:4010UniProt:P35637
SS18Protein SSXTCandidate gene tested inRestrito
FUNÇÃO

Appears to function synergistically with RBM14 as a transcriptional coactivator. Isoform 1 and isoform 2 function in nuclear receptor coactivation. Isoform 1 and isoform 2 function in general transcriptional coactivation. Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:29374058)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (6)
Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)Formation of the embryonic stem cell BAF (esBAF) complexFormation of the canonical BAF (cBAF) complexFormation of the non-canonical BAF (ncBAF) complexRegulation of MITF-M-dependent genes involved in pigmentation
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
66.2 TPM
Nervo tibial
61.8 TPM
Tireoide
54.6 TPM
Útero
53.8 TPM
Cervix Endocervix
53.8 TPM
OUTRAS DOENÇAS (1)
synovial sarcoma
HGNC:11340UniProt:Q15532
TAF15Transcription initiation factor TFIID subunit 12Candidate gene tested inAltamente restrito
FUNÇÃO

The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 an

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (9)
Regulation of TP53 Activity through PhosphorylationRNA Polymerase II Promoter EscapeRNA Polymerase II HIV Promoter EscapeRNA Polymerase II Pre-transcription EventsHIV Transcription Initiation
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
199.6 TPM
Testículo
191.9 TPM
Fibroblastos
180.0 TPM
Esôfago - Muscular
141.2 TPM
Útero
137.9 TPM
OUTRAS DOENÇAS (2)
extraskeletal myxoid chondrosarcomaamyotrophic lateral sclerosis
HGNC:11547UniProt:Q16514
NUTM2BNUT family member 2BCandidate gene tested inAltamente restrito
LOCALIZAÇÃO

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
0.9 TPM
Pituitária
0.4 TPM
Cerebelo
0.3 TPM
Rim - Medula
0.3 TPM
Baço
0.3 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (2)
clear cell sarcoma of kidneyendometrioid stromal sarcoma
HGNC:23445UniProt:A6NNL0
NF1NeurofibrominCandidate gene tested inAltamente restrito
FUNÇÃO

Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity

LOCALIZAÇÃO

NucleusNucleus, nucleolusCell membrane

VIAS BIOLÓGICAS (1)
RAS signaling downstream of NF1 loss-of-function variants
MECANISMO DE DOENÇA

Neurofibromatosis 1

A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
17.9 TPM
Cérebro - Hemisfério cerebelar
17.1 TPM
Cerebelo
15.3 TPM
Nervo tibial
14.9 TPM
Tireoide
14.1 TPM
OUTRAS DOENÇAS (12)
neurofibromatosis, familial spinalneurofibromatosis type 1juvenile myelomonocytic leukemiaWatson syndrome
HGNC:7765UniProt:P21359
ASPSCR1Tether containing UBX domain for GLUT4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Tethering protein that sequesters GLUT4-containing vesicles in the cytoplasm in the absence of insulin. Modulates the amount of GLUT4 that is available at the cell surface (By similarity). Enhances VCP methylation catalyzed by VCPKMT

LOCALIZAÇÃO

Endomembrane systemEndoplasmic reticulum-Golgi intermediate compartment membraneCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Translocation of SLC2A4 (GLUT4) to the plasma membrane
OUTRAS DOENÇAS (2)
alveolar soft part sarcomaMIT family translocation renal cell carcinoma
HGNC:13825UniProt:Q9BZE9
NR4A3Nuclear receptor subfamily 4 group A member 3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes (By similarity). Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
MECANISMO DE DOENÇA

Ewing sarcoma

A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
41.6 TPM
Adipose Visceral Omentum
35.6 TPM
Ovário
31.6 TPM
Coração - Átrio
21.7 TPM
Fallopian Tube
16.6 TPM
OUTRAS DOENÇAS (1)
extraskeletal myxoid chondrosarcoma
HGNC:7982UniProt:Q92570
PAX3Paired box protein Pax-3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor that may regulate cell proliferation, migration and apoptosis. Involved in neural development and myogenesis. Transcriptional activator of MITF, acting synergistically with SOX10 (PubMed:21965087)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
Specification of the neural plate borderTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Waardenburg syndrome 1

WS1 is an autosomal dominant disorder characterized by non-progressive sensorineural deafness, pigmentary disturbances such as frontal white blaze of hair, heterochromia of irides, white eyelashes, leukoderma, and wide bridge of nose owing to lateral displacement of the inner canthus of each eye (dystopia canthorum). WS1 shows variable clinical expression and some affected individuals do not manifest hearing impairment or iris pigmentation disturbances. Dystopia canthorum is the most consistent sign and is found in 98% of the patients.

EXPRESSÃO TECIDUAL(Baixa expressão)
Glândula salivar
4.6 TPM
Cerebelo
4.0 TPM
Cérebro - Hemisfério cerebelar
2.3 TPM
Skin Not Sun Exposed Suprapubic
2.3 TPM
Testículo
2.1 TPM
OUTRAS DOENÇAS (4)
Waardenburg syndrome type 1alveolar rhabdomyosarcomaWaardenburg syndrome type 3craniofacial-deafness-hand syndrome
HGNC:8617UniProt:P23760
SLC67A1Solute carrier family 67 member A1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a transporter of organic cations based on a proton efflux antiport mechanism. May play a role in the transport of chloroquine and quinidine-related compounds in kidney (PubMed:9744804). Plays a role in the regulation of lipid metabolism (By similarity)

LOCALIZAÇÃO

Apical cell membrane

VIAS BIOLÓGICAS (1)
SLC-mediated transport of organic cations
MECANISMO DE DOENÇA

Lung cancer

A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

OUTRAS DOENÇAS (3)
lung cancerembryonal rhabdomyosarcomahereditary breast carcinoma
HGNC:10964UniProt:Q96BI1
DICER1Endoribonuclease DicerDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing. Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing complex (RISC) to complementary RNAs to degrade them

LOCALIZAÇÃO

CytoplasmCytoplasm, perinuclear region

VIAS BIOLÓGICAS (5)
MicroRNA (miRNA) biogenesisSmall interfering RNA (siRNA) biogenesistRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesisM-decay: degradation of maternal mRNAs by maternally stored factorsRegulation of MITF-M-dependent genes involved in apoptosis
MECANISMO DE DOENÇA

Pleuropulmonary blastoma

A rare pediatric intrathoracic neoplasm. The tumor arises from the lung, pleura, or both, and appears to be purely mesenchymal in phenotype. It lacks malignant epithelial elements, a feature that distinguishes it from the classic adult-type pulmonary blastoma. It arises during fetal lung development and is often part of an inherited cancer syndrome. The tumor contain both epithelial and mesenchymal cells. Early in tumorigenesis, cysts form in lung airspaces, and these cysts are lined with benign-appearing epithelium. Mesenchymal cells susceptible to malignant transformation reside within the cyst walls and form a dense layer beneath the epithelial lining. In a subset of patients, overgrowth of the mesenchymal cells produces a sarcoma, a transition that is associated with a poorer prognosis. Some patients have multilocular cystic nephroma, a benign kidney tumor.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
46.1 TPM
Tireoide
31.6 TPM
Cervix Endocervix
31.4 TPM
Útero
31.2 TPM
Ovário
30.2 TPM
OUTRAS DOENÇAS (10)
pleuropulmonary blastomaglobal developmental delay - lung cysts - overgrowth - Wilms tumor syndromegoiter, multinodular 1, with or without Sertoli-Leydig cell tumorsrhabdomyosarcoma, embryonal, 2
HGNC:17098UniProt:Q9UPY3
PAX7Paired box protein Pax-7Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor that is involved in the regulation of muscle stem cells proliferation, playing a role in myogenesis and muscle regeneration

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Specification of the neural plate border
MECANISMO DE DOENÇA

Rhabdomyosarcoma 2

A form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchymal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas.

EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Frontal Cortex BA9
1.7 TPM
Músculo esquelético
1.5 TPM
Córtex cerebral
1.3 TPM
Brain Anterior cingulate cortex BA24
0.5 TPM
Brain Spinal cord cervical c-1
0.4 TPM
OUTRAS DOENÇAS (2)
alveolar rhabdomyosarcomamyopathy, congenital, progressive, with scoliosis
HGNC:8621UniProt:P23759
SSX1Protein SSX1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Could act as a modulator of transcription (PubMed:7539744). Plays a role in spermatogenesis (PubMed:36796361)

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, flagellum axoneme

VIAS BIOLÓGICAS (1)
Negative Regulation of CDH1 Gene Transcription
MECANISMO DE DOENÇA

Spermatogenic failure, X-linked, 5

A male infertility disorder characterized by reduced progressive sperm motility and multiple morphologic sperm abnormalities, resulting in asthenoteratozoospermia.

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
15.5 TPM
Tireoide
0.3 TPM
OUTRAS DOENÇAS (3)
synovial sarcomaspermatogenic failure, X-linked, 5obsolete non-syndromic male infertility due to sperm motility disorder
HGNC:11335UniProt:Q16384
SMARCB1SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Core component of the BAF (hSWI/SNF) complex. This ATP-dependent chromatin-remodeling complex plays important roles in cell proliferation and differentiation, in cellular antiviral activities and inhibition of tumor formation. The BAF complex is able to create a stable, altered form of chromatin that constrains fewer negative supercoils than normal. This change in supercoiling would be due to the conversion of up to one-half of the nucleosomes on polynucleosomal arrays into asymmetric structures

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (8)
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not knownRMTs methylate histone argininesFormation of neuronal progenitor and neuronal BAF (npBAF and nBAF)Formation of the embryonic stem cell BAF (esBAF) complexFormation of the polybromo-BAF (pBAF) complex
MECANISMO DE DOENÇA

Rhabdoid tumor predisposition syndrome 1

A familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
136.4 TPM
Testículo
110.5 TPM
Cérebro - Hemisfério cerebelar
98.7 TPM
Cerebelo
93.5 TPM
Ovário
93.2 TPM
OUTRAS DOENÇAS (9)
rhabdoid tumor predisposition syndrome 1intellectual disability, autosomal dominant 15familial multiple meningiomaschwannomatosis
HGNC:11103UniProt:Q12824

Medicamentos aprovados (FDA)

2 medicamentos encontrados nos registros da FDA americana.

💊 Doxorubicin Hydrochloride (DOXORUBICIN HYDROCHLORIDE)
💊 Pazopanib (PAZOPANIB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

186 variantes patogênicas registradas no ClinVar.

🧬 FOXO1: GRCh37/hg19 13q13.1-21.32(chr13:33738980-68435696)x1 ()
🧬 FOXO1: GRCh37/hg19 13q12.3-14.3(chr13:32076445-54495559)x1 ()
🧬 FOXO1: GRCh37/hg19 13q11-31.3(chr13:19436287-92292639)x3 ()
🧬 FOXO1: GRCh37/hg19 13q13.2-21.1(chr13:35015723-59553519)x3 ()
🧬 FOXO1: GRCh37/hg19 13q13.2-14.11(chr13:35060982-44540846)x1 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1 variantes classificadas pelo ClinVar.

1
VUS (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
HRAS: NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) [Uncertain significance]

Vias biológicas (Reactome)

195 vias biológicas associadas aos genes desta condição.

AKT phosphorylates targets in the nucleus Regulation of gene expression in beta cells AKT-mediated inactivation of FOXO1A Constitutive Signaling by AKT1 E17K in Cancer MAPK6/MAPK4 signaling Interleukin-4 and Interleukin-13 signaling Regulation of localization of FOXO transcription factors FOXO-mediated transcription of cell death genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Regulation of FOXO transcriptional activity by acetylation FOXO-mediated transcription of cell cycle genes PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Receptor-type tyrosine-protein phosphatases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling NTF3 activates NTRK3 signaling Signaling by NTRK3 (TRKC) Activated NTRK3 signals through PLCG1 Activated NTRK3 signals through RAS Activated NTRK3 signals through PI3K NTRK3 as a dependence receptor Transcriptional regulation of granulopoiesis SCF(Skp2)-mediated degradation of p27/p21 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence RMTs methylate histone arginines Transcriptional regulation of white adipocyte differentiation Cyclin D associated events in G1 Ubiquitin-dependent degradation of Cyclin D PTK6 Regulates Cell Cycle Transcriptional regulation by RUNX2 Meiotic recombination Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity SPOP-mediated proteasomal degradation of PD-L1(CD274) Signaling by membrane-tethered fusions of PDGFRA or PDGFRB Signaling by FLT3 fusion proteins NoRC negatively regulates rRNA expression B-WICH complex positively regulates rRNA expression Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Deposition of new CENPA-containing nucleosomes at the centromere COPII-mediated vesicle transport Signaling by ALK fusions and activated point mutants Degradation of the extracellular matrix Interleukin-7 signaling Formation of the beta-catenin:TCF transactivating complex Chromatin modifying enzymes RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known EGR2 and SOX10-mediated initiation of Schwann cell myelination Negative Regulation of CDH1 Gene Transcription Regulation of MITF-M-dependent genes involved in pigmentation Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) Formation of the canonical BAF (cBAF) complex Formation of the polybromo-BAF (pBAF) complex Formation of the embryonic stem cell BAF (esBAF) complex Formation of the non-canonical BAF (ncBAF) complex Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) Formation of Senescence-Associated Heterochromatin Foci (SAHF) AKT phosphorylates targets in the cytosol SUMOylation of transcription factors SUMOylation of ubiquitinylation proteins Trafficking of AMPA receptors Ub-specific processing proteases Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation Stabilization of p53 Regulation of RUNX3 expression and activity Degradation of CDH1 NPAS4 regulates expression of target genes Transcriptional regulation of testis differentiation Nephron development Platelet degranulation Downstream signal transduction Signaling by PDGF Non-integrin membrane-ECM interactions RAF/MAP kinase cascade GPVI-mediated activation cascade Collagen degradation Fibronectin matrix formation Collagen biosynthesis and modifying enzymes Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Assembly of collagen fibrils and other multimeric structures Cell surface interactions at the vascular wall Integrin cell surface interactions Anchoring fibril formation Crosslinking of collagen fibrils Syndecan interactions ECM proteoglycans Scavenging by Class A Receptors GP1b-IX-V activation signalling Platelet Adhesion to exposed collagen Platelet Aggregation (Plug Formation) MET activates PTK2 signaling RUNX2 regulates osteoblast differentiation Collagen chain trimerization Enhanced cleavage of VWF variant by ADAMTS13 Enhanced binding of GP1BA variant to VWF multimer:collagen Defective VWF cleavage by ADAMTS13 variant Defective VWF binding to collagen type I Defective binding of VWF variant to GPIb:IX:V Developmental Lineage of Pancreatic Ductal Cells Response of EIF2AK4 (GCN2) to amino acid deficiency Response of EIF2AK1 (HRI) to heme deficiency Cellular response to mitochondrial stress Myogenesis RUNX1 regulates transcription of genes involved in differentiation of HSCs NGF-stimulated transcription TGFBR3 expression Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Signaling by Hippo NADE modulates death signalling Regulation of PLK1 Activity at G2/M Transition Regulation of HSF1-mediated heat shock response HSF1 activation Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex AURKA Activation by TPX2 Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models RAB GEFs exchange GTP for GDP on RABs SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways Transcriptional and post-translational regulation of MITF-M expression and activity Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation DNA Damage/Telomere Stress Induced Senescence Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis Ovarian tumor domain proteases TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors CREB3 factors activate genes Invadopodia formation CDC42 GTPase cycle Telomere Extension By Telomerase Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence KCNH2 SPOP SPOP ER-to-ERGIC v-SNARES ER-to-ERGIC v-SNARES ER-to-ERGIC v-SNARES ERGIC-to-cis-Golgi cargo ERGIC-to-cis-Golgi cargo ERGIC-to-cis-Golgi cargo Regulation of CDH19 Expression and Function mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA mRNA Polyadenylation Dengue Virus-Host Interactions HIV Transcription Initiation RNA Polymerase II HIV Promoter Escape Transcription of the HIV genome HATs acetylate histones RNA Polymerase II Pre-transcription Events RNA Polymerase II Promoter Escape RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Initiation And Promoter Clearance Regulation of RAS by GAPs RAS signaling downstream of NF1 loss-of-function variants Nuclear Receptor transcription pathway RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function Specification of the neural plate border SLC-mediated transport of organic cations Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1) MicroRNA (miRNA) biogenesis Small interfering RNA (siRNA) biogenesis tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis M-decay: degradation of maternal mRNAs by maternally stored factors Regulation of MITF-M-dependent genes involved in apoptosis Regulation of CDH1 Gene Transcription

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 27
1Fase 17
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Sarcoma de tecidos moles

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

10 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

2.973 ensaios clínicos encontrados, 16 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
6.427 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 6.427

#1

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332.

Pediatric blood &amp; cancer2026 Mar 16

Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332. Patients were treated with risk-adapted therapy, including surgery with or without radiotherapy and ifosfamide and doxorubicin. Twenty-four patients with ASPS enrolled on ARST0332 between 2007 and 2012 were analyzed. The majority of primaries were extremity tumors (71%) and > 5 cm (54%). Nearly half (46%) of patients had metastatic disease at diagnosis, all of whom had primary tumors > 5 cm and pulmonary metastases with or without extrapulmonary metastases. Six patients were evaluable for response to neoadjuvant chemoradiotherapy without an objective response. Estimated 5-year event-free survival (EFS) and overall survival (OS) were 91% and 100% for low-risk (n = 11), 0% and 50% for intermediate-risk (n = 2), and 0% and 59% for high-risk disease (n = 11), respectively. EFS and OS differed significantly by maximal tumor diameter, presence or absence of metastatic disease, risk group, treatment arm, and upfront primary site resection status. Patients with low-risk ASPS (non-metastatic, grossly resected tumors ≤ 5 cm) had excellent outcomes with surgery with or without radiation on ARST0332. Chemotherapy has been reported to be generally ineffective in ASPS and, indeed, there were no objective responses to neoadjuvant chemoradiotherapy on ARST0332. All patients treated with combination chemoradiotherapy ultimately developed disease progression/relapse. A different therapeutic approach is needed for patients with unresectable or metastatic ASPS.

#2

Local Control of Bladder/Prostate Rhabdomyosarcoma: An Expert Consensus Guideline From the International Soft Tissue Sarcoma Consortium (INSTRuCT).

Pediatric blood &amp; cancer2026 Mar 13

The local treatment of bladder and prostate rhabdomyosarcoma is a multidisciplinary decision, incorporating elements of patient age, tumor size and location, nodal involvement, and access to local expertise and technology. The relative absence of long-term bladder and bowel function outcome data complicates discussions, particularly given improved survival rates and development of new surgical and radiotherapy techniques. These INSTRuCT guidelines, a collaboration of the Children's Oncology Group, Soft Tissue Sarcoma Committee, European Pediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe, reflect international expert consensus and are intended to inform practice, generate discussion, and highlight areas of future inquiry.

#3

VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma.

International journal of biological sciences2026

The ERK5 signaling pathway has recently emerged as a critical regulator of soft tissue sarcoma (STS) biology, contributing to tumor initiation, progression, and maintenance. In this study, we identify VCAN, a chondroitin sulfate proteoglycan, as a novel transcriptional target of ERK5 and a central mediator of ERK5-related oncogenesis. Through a combination of genetic (silencing, overexpression) and pharmacological approaches, applied in both a chemically induced murine sarcoma model and several human STS cell lines, we demonstrate that ERK5 positively regulates VCAN expression. Functionally, VCAN silencing (by shRNAs) recapitulates the phenotypes of ERK5 silencing, including impaired migration, adhesion, proliferation, and tumorigenesis. Conversely, VCAN overexpression rescues these effects, confirming its essential role in ERK5-mediated oncogenesis. Furthermore, transcriptomic profiling reveals that VCAN accounts for a substantial portion of ERK5-regulated gene expression program. Analyses of human STS patient samples reveal significantly elevated mRNA levels of both VCAN and ERK5 compared to normal tissues. Notably, a strong correlation between VCAN and ERK5 expression, both at mRNA and protein levels, emerged in biopsies from leiomyosarcomas and undifferentiated pleomorphic sarcomas. Together, these findings uncover VCAN as a key effector in ERK5-driven tumorigenesis and highlight the ERK5/VCAN signaling axis as a promising therapeutic target in soft tissue sarcomas.

#4

A Phase 1 Study of Neoadjuvant Cabozantinib in Combination With Radiation Therapy for Sarcomas of the Extremities.

American journal of clinical oncology2026 Feb 23

Cabozantinib demonstrates activity in multiple soft tissue sarcoma (STS) subtypes, but use with concurrent radiation therapy (RT) has been limited by concern for risk of fistula or perforation. This phase 1 trial evaluated the safety of concurrent cabozantinib and RT as neoadjuvant therapy in patients with extremity STS. Adults with newly diagnosed localized extremity STS planned for neoadjuvant RT and surgical resection were eligible. Participants received radiation with 5000 to 5040 cGy with conventional fractionation and cabozantinib 40 mg or 60 mg daily. Patients were observed for dose-limiting toxicity (DLT) up to 28 days after completion of concurrent cabozantinib/RT. The primary objective was to identify a recommended phase 2 dose (RP2D) of cabozantinib for combination with RT, and secondary objectives included estimating rates of treatment-related adverse event (TRAE), margin positivity, and objective response. Six patients were enrolled with histologic subtypes of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, leiomyosarcoma, and myxoid liposarcoma. No DLT due to the combination of cabozantinib and radiation was observed, but 3/6 (50%) patients required dose-reduction due to TRAE of cabozantinib alone. No grade ≥3 toxicities were attributed to RT. The RP2D was cabozantinib 60 mg. Six (100%) patients demonstrated stable disease at 12 weeks, and 5 (83%) underwent R0 resection. Two (33%) patients experienced metastatic relapse, and 1 (17%) died without relapse; 3 (50%) patients survived without relapse by last contact. No local recurrences occurred. In this phase 1 trial, concurrent cabozantinib/RT was feasible and demonstrated an acceptable safety profile for patients with extremity STS.

#5

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.

Frontiers in cell and developmental biology2026

Rhabdomyosarcoma (RMS) is the most prevalent soft tissue sarcoma in children, and despite advances in multimodal therapy, progress in improving the survival of high-risk patients has been limited. Increasing evidence indicates that epigenetic dysregulation contributes to RMS pathogenesis and therapeutic resistance, particularly through aberrant activity of histone deacetylases (HDACs). HDAC inhibitors (HDACi) have shown promise in preclinical RMS models, showing enhancing of the efficacy of standard chemotherapies and radiotherapy. This mini-review summarizes recent studies exploring HDAC inhibition in combination with first-line therapies, examines the mechanistic basis for therapeutic synergy, and discusses opportunities and challenges in translating HDACi-based combinations to the clinic. By integrating mechanistic insights with translational evidence, this review outlines current progress and proposes future directions for development of HDACi-enhanced treatment strategies for this aggressive pediatric malignancy.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC4.685 artigos no totalmostrando 197

2026

Collision Tumor of Metastatic Lung Adenocarcinoma to Lower Limb Leiomyosarcoma: Case Report and Literature Review.

International journal of surgical pathology
2026

Superficial Rhabdomyosarcomas: A Review of Subtypes, Diagnostic Features, and Differential Diagnoses.

International journal of surgical pathology
2026

Immune cell clustering identifies a CD163⁺/CSF1R⁺ macrophage and neutrophil-enriched phenotype with distinct biological signatures and poor prognosis in angiosarcoma.

Oncoimmunology
2026

Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcoma.

Frontiers in immunology
2026

Axial Round Cell Sarcoma Harboring a Non-ETS EWSR1 Rearrangement: Diagnostic Challenges and Clinical Implications.

Cureus
2026

The effect of neoadjuvant radiotherapy on immune cell infiltrates in myxofibrosarcoma.

Immuno-oncology technology
2026

Cervical embryonal rhabdomyosarcoma beyond childhood: A case report and literature review.

Radiology case reports
2026

Prophylactic Lymphedema Surgery During Soft Tissue Sarcoma Resection: Surgical Technique Step by Step.

Plastic and reconstructive surgery. Global open
2026

Anthropometric factors, physical activity, and the risk of soft tissue sarcoma: a case-control study.

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
2026

Reduced initial Pazopanib dosing strategy for recurrent, advanced, or metastatic sarcoma: A single center experience.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
2026

Peritoneal Sarcomatosis Secondary to Conventional Chondrosarcoma: A Case Report.

Cureus
2026

Perforator versus traditional flaps in extremity soft-tissue sarcoma reconstruction: A comparative cohort study.

Journal of plastic, reconstructive &amp; aesthetic surgery : JPRAS
2026

Revisiting the Immune Frontier in Soft Tissue Sarcomas.

Current oncology reports
2026

Efficacy of Ultrasonic Scalpel in Orthopaedic Oncology Surgery: An Initial Patient Cohort Study Based on Propensity Score Matching Analysis.

The Journal of the American Academy of Orthopaedic Surgeons
2026

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332.

Pediatric blood &amp; cancer
2026

RNA-binding Protein NMD3 Promotes Osteosarcoma Cell Proliferation Via Regulating mTOR Signaling Pathway, Exerting Adverse Impacts on Patient Prognosis.

Applied biochemistry and biotechnology
2026

A rare presentation of uterine cavity embryonal rhabdomyosarcoma in a preschool girl: a case report.

International journal of surgery case reports
2026

Primary subcutaneous inguinal malignant melanoma mimicking a soft tissue sarcoma.

International journal of surgery case reports
2026

Computed Tomography Features of Pulmonary Metastatic Nodules Help Narrow the Differential Diagnosis of the Primary Tumor.

Veterinary radiology &amp; ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
2026

Intramuscular Myxoma: Results from the Largest European Single-Center Study-Clinical and Pathological Findings and Syndromal Associations.

Diagnostics (Basel, Switzerland)
2026

The Extracellular Matrix Regulates Invasion in Fusion-Negative Rhabdomyosarcoma via YAP-PIEZO1 Signaling Axis.

Cancers
2026

Low Survival Rates for Pediatric Patients with Tumor Thrombus in Sarcoma.

Journal of clinical medicine
2026

Predicting the Postoperative Recurrence Risk in Soft-Tissue Sarcomas of the Extremities and Trunk Using MRI-Based Nomogram.

Academic radiology
2026

Local Control of Bladder/Prostate Rhabdomyosarcoma: An Expert Consensus Guideline From the International Soft Tissue Sarcoma Consortium (INSTRuCT).

Pediatric blood &amp; cancer
2026

Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium.

European journal of cancer (Oxford, England : 1990)
2026

Tumor habitat characteristics derived from intravoxel incoherent motion for early response assessment in soft tissue sarcoma undergoing neoadjuvant radiotherapy and targeted therapy: a phase II study.

Translational cancer research
2026

Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem‑ion): Interim report of a randomized phase II pilot trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
2026

Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow.

JCO global oncology
2026

Undifferentiated testicular pleomorphic sarcoma: A case report.

World journal of clinical cases
2026

Computed tomography-based nutritional associated nomogram on machine learning predicts survival outcomes in patients with resectable soft-tissue sarcoma.

World journal of radiology
2026

Timing and Frequency of Surveillance After Resection of Extremity and Trunk Soft Tissue Sarcoma: Identifying Opportunities for Improvement.

Annals of surgical oncology
2026

Patient perspectives on recovery and satisfaction after hemipelvectomy for pelvic tumors.

Surgical oncology
2026

Machine learning and logistic regression in estimating survival in patients with high-malignant deep-seated soft tissue sarcomas: development and analysis based on a population-based retrospective cohort.

Acta orthopaedica
2026

VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma.

International journal of biological sciences
2026

Endovascular Thrombectomy in a Patient with Acute Ischemic Stroke due to Tumor Emboli Associated with Cardiac Metastasis of Extraskeletal Myxoid Chondrosarcoma: A Case Report.

NMC case report journal
2026

Concurrent Monkeypox, HHV8, and Other Opportunistic Infections in a Human Immunodeficiency Virus Patient with Disseminated Kaposi Sarcoma: A Case Report.

Case reports in oncology
2026

Perifascial Nodular Fasciitis Adjacent to the Tensor Fasciae Latae: Ultrasound and MRI Findings in a Rare Hip Presentation.

Cureus
2026

A Rapidly Progressing Lower Extremity Soft Tissue Sarcoma in an Adolescent Patient.

Cureus
2026

Laparoscopic Reconstructive Repair of Uterine and Rectal Prolapse with Posterior Perineal Hernia after Wide Resection of Soft-tissue Sarcoma of the Buttocks: A Case Report.

Gynecology and minimally invasive therapy
2026

Epithelioid Sarcoma of the Forearm in a 70-Year-Old Woman: A Case Report at a Referral Facility in Tanzania.

Clinical case reports
2025

Effectiveness of interstitial brachytherapy in extremity sarcoma-treatment outcomes and current concepts.

Indian journal of cancer
2026

Preventing unplanned "whoops" sarcoma surgery: from technical pearls to early referral and network-level quality metrics.

Chinese clinical oncology
2026

Tumour localization and oncological outcomes in nonuterine leiomyosarcoma of the abdomen and pelvis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2026

FOXM1 inhibitor, RCM‑1, enhances venetoclax mediated apoptosis through downregulation of ATP2B4 in rhabdomyosarcoma.

International journal of oncology
2026

The analysis of biodistribution and tumor uptake of [18F]AlF-FAPI-74 in patients with soft tissue sarcoma and gastro-intestinal tumors compared with [18F]FDG in a prospective, exploratory study.

EJNMMI reports
2026

Association of surgical resection with survival in retroperitoneal leiomyosarcoma based on SEER propensity score matching and machine-learning models.

Scientific reports
2026

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results.

Cancer discovery
2026

Breathless and Beyond: Anterior Mediastinal Malignant Peripheral Nerve Sheath Tumor as a Rare Neurofibromatosis Type 1 Manifestation.

Clinical case reports
2026

Performance of deep learning-based segmentation of soft tissue sarcoma by MRI sequence, tumor type and location.

Skeletal radiology
2026

A Rapidly Growing Cervical Tumor in an Infant: Sarcoma with BCOR Gene Alterations.

International journal of surgical pathology
2026

Cytologic, Histologic, and Ultrastructural Findings of Spontaneous, Cutaneous Fibrosarcoma in a Koi.

Veterinary clinical pathology
2026

Increased Uptake of 68Ga-DOTA-IBA in Sclerosing Epithelioid Fibrosarcoma.

Clinical nuclear medicine
2026

Desmoplastic Small Round Blue Cell Tumor in a Young Adult Man: A Rare Case of Abdominal Sarcoma.

The American journal of case reports
2026

A Phase 1 Study of Neoadjuvant Cabozantinib in Combination With Radiation Therapy for Sarcomas of the Extremities.

American journal of clinical oncology
2026

Atypical bone lesion of the fifth metatarsal bone in an HIV-positive patient: A challenging radiologic-pathologic correlation of tuberculous osteomyelitis.

Radiology case reports
2026

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.

Frontiers in cell and developmental biology
2026

Case Report: An uncommon germline variant of familial GISTs: broadening the landscape of inherited GIST syndromes.

Frontiers in oncology
2026

Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.

Molecular therapy. Oncology
2026

When AI joins the table: evaluating large language model performance in soft tissue sarcoma tumor board decisions.

Journal of cancer research and clinical oncology
2026

Targeting tRNA-Arg-TCT-4-1 suppresses cancer cell growth and tumorigenesis.

bioRxiv : the preprint server for biology
2026

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models.

bioRxiv : the preprint server for biology
2026

Comparative modes of chromatin engagement by PAX::FOXO1 fusions in rhabdomyosarcoma.

bioRxiv : the preprint server for biology
2026

Bioinformatic Analysis to Identify Biomarker Candidates of Complex Karyotype Soft Tissue Sarcomas with CDK4-Amplification.

Biomolecules &amp; therapeutics
2026

A series of extraskeletal myxoid chondrosarcomas with rare morphological and molecular variations.

Histopathology
2026

Management of Great Saphenous Vein and Inferior Vena Cava Leiomyosarcomas: Two Surgical Case Reports and Literature Review.

Journal of clinical medicine
2026

Clinical Characteristics of Complex Karyotype Soft Tissue Sarcomas: A Single-Institution Cohort Study.

Medicina (Kaunas, Lithuania)
2026

Tyrosine-Peptide Analog Modulates Extracellular Vesicles miRNAs Cargo from Mesenchymal Stem/Stromal and Cancer Cells to Drive Immunoregeneration and Tumor Suppression.

Biomolecules
2026

Canine peritoneal and pleural larval mesocestoidosis with sarcoma development.

Veterinary parasitology, regional studies and reports
2026

Dermatofibrosarcoma protuberans: A clinical review of diagnosis and management.

Journal of the American Academy of Dermatology
2026

Superficial Tumor Location and Adiposity as Independent Predictors of Postoperative Wound Complications in Sarcoma Resections of the Thigh.

Journal of surgical oncology
2026

[Particle radiotherapy for sarcomas : Advantages, challenges and future perspectives].

Radiologie (Heidelberg, Germany)
2026

Trabectedin in the treatment of soft tissue sarcoma: Real-world data on effectiveness, safety, and financial implications from a European comprehensive cancer center.

International journal of cancer
2026

Molecular epidemiology of the expression of urokinase plasminogen activator receptor-associated protein (uPARAP) in mesenchymal malignancies.

Translational oncology
2026

Prognostic determinants and survival outcomes in epithelioid sarcoma: A contemporary population-based analysis of 1123 patients.

Medicine
2026

Comprehensive genomic profiling refines diagnosis and reveals clinically relevant alterations in pediatric Soft tissue sarcomas.

European journal of medical research
2026

An Atypical Presentation of Cutaneous Angiosarcoma: A Diagnostic Challenge in an End-Stage Renal Disease Patient.

Cureus
2026

Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternational Soft Tissue saRcoma ConsorTium (INSTRuCT).

Cancer medicine
2026

Percutaneous Cryoablation for the Management of Bone and Soft Tissue Tumors.

Seminars in musculoskeletal radiology
2026

The impact of non-centralised surgical treatment on local recurrence, amputation rate and survival in patients with extremity soft tissue sarcoma.

European journal of orthopaedic surgery &amp; traumatology : orthopedie traumatologie
2026

Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.

Scientific reports
2026

Leiomyosarcoma With Dedifferentiation Mimicking a Benign Neoplasm.

The American Journal of dermatopathology
2026

CAR-T cell immunotherapy in rhabdomyosarcoma.

Journal of translational medicine
2026

Interdisciplinary therapy of extremity soft tissue sarcomas: current evidence on systemic treatments and the role of reconstructive surgery.

Innovative surgical sciences
2026

Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology.

Oncology and therapy
2026

PATIENTS WITH SOFT TISSUE SARCOMA AFTER TREATMENT BY NON ORTHOPEDIC ONCOLOGIC SURGEONS: EPIDEMIOLOGICAL PROFILE, STAGING, AND THERAPEUTIC CHALLENGES.

Acta ortopedica brasileira
2026

Real-World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort.

Cancer medicine
2026

Multiple preoperative biopsies may increase histologic grade accuracy in canine soft tissue sarcoma: a prospective study.

Veterinary journal (London, England : 1997)
2026

Comparable Diagnostic Performance of 68Ga-FAPI and 18F-FDG PET/CT in Perineal Rhabdomyosarcoma.

Clinical nuclear medicine
2026

Stewart-Treves syndrome: A fatal complication of rheumatoid arthritis-associated massive lymphedema.

JAAD case reports
2026

Low-Grade Fibromyxoid Sarcoma and Related Subtypes: A Systematic Review and Pooled Analysis of 773 Cases.

Cancers
2026

Radiomics of soft tissue sarcoma metastases to assess prognostic factors related to intrapatient intertumor heterogeneity.

Translational cancer research
2025

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN
2026

Predictive Value of Pretreatment SUVmax on 18 F-FDG PET Imaging for Survival Outcomes of Synovial Sarcoma in Pediatric Patients.

Journal of pediatric hematology/oncology
2026

Gemcitabine-docetaxel therapy in pediatric patients with relapsed or refractory sarcoma: a single-center experience.

Frontiers in pediatrics
2026

Number of affected lymph nodes predicts outcome in extremity rhabdomyosarcoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2026

Preoperative hypofractionated radiotherapy in soft tissue sarcomas: institutional experience and clinical implications.

Clinical and translational radiation oncology
2026

BAF complex-independent gene activation by SS18::SSX.

bioRxiv : the preprint server for biology
2026

Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study.

Cancer
2026

MRI findings for differentiating benign and malignant soft tissue tumors: a systematic review-part 2: key imaging findings.

Skeletal radiology
2026

Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network.

ESMO open
2026

Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research
2026

Malignant nodular fasciitis, a rare manifestation of a benign disease: case report.

Frontiers in oncology
2026

The emerging role of mixed reality and artificial intelligence in sarcoma care: A systematic review.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2026

Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research
2025

Intratumoral habitat and peritumor radiomics for progression risk stratification of patients with soft tissue sarcoma: a multicenter study.

Frontiers in oncology
2026

Long-term clinical outcome of lung radiofrequency ablation in patients with musculoskeletal sarcoma.

International journal of clinical oncology
2026

The anti-apoptotic protein lifeguard is expressed in osteosarcoma, chondrosarcoma and soft tissue sarcoma.

Oncology
2026

A systematic review and meta-analysis of pazopanib efficacy and adverse effects in sarcomas.

Journal of translational medicine
2026

High-risk soft-tissue sarcomas in elderly patients: does perioperative radiotherapy improve local control and prognosis?

BMC cancer
2026

Clear cell sarcoma : a retrospective review from a tertiary orthopaedic sarcoma unit.

The bone &amp; joint journal
2026

Describing the Mutational Characteristics of Myxofibrosarcoma: An AACR Project GENIE Analysis.

Anticancer research
2026

Harnessing AACR Project GENIE to Define the Molecular Features of Desmoplastic Small Round Cell Tumor.

Current issues in molecular biology
2025

Radiotherapy Combined with Immune Checkpoint Inhibitor on Murine Fibrosarcoma and a Narrative Review of Clinical Studies.

Current issues in molecular biology
2026

Radiotherapy Response Prediction in Myxofibrosarcomas and Undifferentiated Soft Tissue Sarcomas Using DNA Methylation and Copy Number Profiling.

International journal of surgical pathology
2026

Discrimination performance in illness-death models with interval-censored disease data.

Statistical methods in medical research
2026

Primary Embryonal Rhabdomyosarcoma of the Breast: A Case Report and Literature Review.

Case reports in oncology
2025

Clinical evaluation, motor performance and quality of life in patients affected by Soft Tissue Sarcomas undergoing surgical treatment: observational study.

Frontiers in oncology
2026

MRI Diffusion Imaging as an Additional Biomarker for Monitoring Chemotherapy Efficacy in Tumors.

Medicina (Kaunas, Lithuania)
2026

First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review.

Cancers
2026

MRI-Based Delta Necrosis as a Prognostic Marker Following Neoadjuvant Chemotherapy in Soft Tissue Sarcoma.

Cancers
2026

Ulcerated nodular fasciitis of the finger mimicking soft tissue sarcoma: a case report.

International cancer conference journal
2026

NTRK-rearranged soft tissue sarcoma that originated from the head and neck with a robust response to the TRK inhibitor larotrectinib.

International cancer conference journal
2025

Role of minimally invasive surgery in paediatric pulmonary metastatic disease.

Ecancermedicalscience
2026

Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas.

Expert review of anticancer therapy
2026

Clinical outcome of 50 patients treated with eribulin for soft tissue sarcoma: a single-institute retrospective study.

Japanese journal of clinical oncology
2026

Outcomes Following Combined Modality Treatment to the Primary Site in Select Patients With Metastatic Soft Tissue Sarcoma.

Practical radiation oncology
2026

Evidence-based quality indicators of soft tissue sarcomas in Germany 2015-2021: An analysis of the German Cancer Registry Group.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2026

Pulmonary metastasectomy from bone and soft tissue sarcomas: defining surgical indications at the time of second pulmonary recurrence.

International journal of clinical oncology
2026

[Hyperthermic isolated limb perfusion with TNF-alpha and melphalan for the treatment of locally advanced soft-tissue sarcoma].

Operative Orthopadie und Traumatologie
2025

[Systemic treatment of bone sarcoma, soft tissue sarcoma, GIST].

La Revue du praticien
2025

[Surgery of soft tissue sarcoma in adults].

La Revue du praticien
2026

Vulvar dermatofibrosarcoma protuberans in a 55-year-old female: A case report, surgical reconstruction approach and literature review.

Gynecologic oncology reports
2026

Effects of a tailored rehabilitation treatment in lower limb Soft Tissue Sarcomas reconstruction: a case series.

Journal of neuroengineering and rehabilitation
2026

Trace element profiles in canine neoplastic disease.

Veterinary journal (London, England : 1997)
2025

Unveiling the myxofibrosarcoma tumor microenvironment: implications for immunotherapy.

Frontiers in immunology
2025

Synovial Sarcoma Arising From the Falciform Ligament.

Cureus
2026

A Primer for Pediatric Plastic Surgeons on Pediatric Head and Neck Malignancies: Part I-Epidemiology and Overview of Common Pediatric Head and Neck Tumors.

Annals of plastic surgery
2026

Alveolar rhabdomyosarcoma with multiple bone marrow metastases: a case report.

BJR case reports
2026

A Real-World Analysis of Outcomes in CIC-Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study.

Cancer medicine
2026

A Rare Case of Recurrent Sarcoma Presenting as an Anterior Mediastinal Mass: Case Report.

Case reports in oncology
2026

Monophasic synovial sarcoma of the thigh in a 60-year-old patient: A rare case report and literature review.

Radiology case reports
2026

A Huge Recurrent Atypical Lipomatous Tumor (Well-Differentiated Liposarcoma) going in to Dedifferentiation 12 years after its First Detection.

Journal of orthopaedic case reports
2025

One case of left atrial arterial intimal sarcoma.

International journal of surgery case reports
2025

Acute sciatic nerve palsy secondary to postoperative seroma following soft tissue sarcoma resection: A case report.

International journal of surgery case reports
2025

Clinical, Cytologic, Histopathologic, and Diagnostic Imaging of a Malignant Peripheral Nerve Sheath Tumor in the Renal Pelvis of a Border Collie Dog.

Veterinary clinical pathology
2026

Proteomic Profiling Reveals Candidate Proteins and Pathways Associated with Chemo-Radio-Sensitivity and Relapse in Rhabdomyosarcoma.

Journal of proteome research
2026

A Causal Discovery Workflow for Rare Diseases: Experts-in-the-Loop Analysis of Sparse Longitudinal Data.

Journal of medical systems
2026

Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor.

Discover oncology
2026

How Do Patient Demographics and Socioeconomic Disadvantage Impact Clinical Presentation, Surgical Outcomes, and Survival for Upper Extremity Soft Tissue Sarcoma?

Cancer reports (Hoboken, N.J.)
2025

The recurrence or metastasis related gene predicts the prognosis of extremity and trunk soft tissue sarcoma.

Precision clinical medicine
2026

Evaluation of magnetic resonance imaging parameters and compliance with guidelines in soft tissue sarcomas.

BMC cancer
2026

Treatment and Outcomes of Children and Adults With Rhabdomyosarcoma in Rwanda.

Pediatric blood &amp; cancer
2026

Clinical Significance and Therapeutic Potential of Long Non-Coding RNA H19 in Soft Tissue Sarcoma.

Cancer medicine
2026

From Numbers to Movement: Making the Toronto Extremity Salvage Score a Living Measure in Soft-tissue Sarcoma Survivorship.

Clinical oncology (Royal College of Radiologists (Great Britain))
2026

Inguinal "neoligament" reconstruction after groin soft tissue sarcoma resection: A novel surgical technique.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2026

Role of Dynamic Contrast-Enhanced MRI in Detecting Post-Treatment Local Recurrence of Soft-Tissue Sarcomas: A Systematic Review and Meta-Analysis.

Diagnostics (Basel, Switzerland)
2025

Total Quadriceps Resection in High-Grade Soft-Tissue Sarcomas of the Thigh: Surgical Technique and Long-Term Functional Outcomes in Surviving Patients.

Cancers
2026

Proteomics analysis of human mesenchymal stromal/stem cell sarcomagenesis model identifies ALDH1A3 and CD99 as potential targets in the transformation process.

BMC biology
2026

How Should Primary Pulmonary Sarcoma be Staged? Results of an International Multicentre Analysis.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
2026

Distinct coexisting pathologies of oral malignant peripheral nerve sheath tumor with melanin pigmentation and indolent small lymphocytic lymphoma.

Discover oncology
2026

Vascular Reconstruction in Extremity Soft Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis.

Journal of surgical oncology
2026

Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysis.

Journal of cancer research and clinical oncology
2025

Tumor Biomarkers in Peripheral Blood Liquid Biopsy of Soft Tissue Sarcomas: Research Progress and Clinical Applications in the Era of Precision Medicine.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
2025

Efficacy of larotrectinib in pediatric cancers with NTRK gene fusions.

Translational pediatrics
2026

Bone and soft tissue sarcoma mortality in 19 811 patients diagnosed in Japan, 2006-2020.

JNCI cancer spectrum
2025

A comparison of upper versus lower extremity rhabdomyosarcoma survival: A SEER database analysis.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
2025

Clinico-Pathological and Clinical Outcomes of Soft Tissue Sarcoma With FUS-TFCP2 or EWSR1-TFCP2 Fusions: A Case Series From North India.

Cureus
2026

Artificial intelligence in cancer genomics: refining diagnosis of hereditary breast and ovarian cancer syndromes.

Annals of medicine and surgery (2012)
2025

Comparison of two validated nomograms in patients with localized soft tissue sarcoma of the extremities and trunk wall.

Chinese clinical oncology
2026

Intratumoral and peritumoral radiomics for the pretreatment prediction of response to neoadjuvant chemotherapy in rhabdomyosarcoma: a multicenter retrospective cohort study.

Insights into imaging
2025

Case Report: Bowel obstruction caused by an adult fibrosarcoma located in the pelvis.

Frontiers in surgery
2026

Robotic-Assisted Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy in Metastatic Pleuropulmonary Leiomyosarcoma: A Case Report.

Case reports in oncological medicine
2025

Case Report: Recurrent phyllodes tumor of the breast with progressive malignant transformation.

Frontiers in oncology
2026

Pedicled latissimus dorsi flap and internal mammary perforator flaps for coverage of the latero-cervico-thoracic area after soft-tissue sarcoma resection: A case report.

Annales de chirurgie plastique et esthetique
2026

Infiltration of the oedema tail with tumour cells in patients with a soft-tissue sarcoma - the predisposing factors and clinical relevance : is the oedema tail contaminated tissue?

The bone &amp; joint journal
2026

Role of Repeat Core Needle Biopsy After Nondiagnostic Initial Biopsy for Soft Tissue and Bone Sarcoma: Systematic Review and Meta-Analysis.

Journal of surgical oncology
2026

Dual role of IFNγ in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity.

Oncology letters
2025

Outcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective study.

JTCVS open
2025

Dermatofibrosarcoma Protuberans of the Clavicular Skin in a 70-Year-Old Woman: Case Report and Management.

Cureus
2026

Reassessing the 8 cm Cutoff: Continuous Tumor Size-Mortality Risk Supports Three-Tier Staging in High Grade Osteosarcoma.

Journal of surgical oncology
2025

Activation of the STING pathway potentiates the antitumor efficacy of doxorubicin in soft-tissue sarcoma.

Frontiers in oncology
2026

Reirradiation for locally recurrent soft tissue sarcomas: A systematic review.

Clinical and translational radiation oncology
2026

Dermatofibrosarcoma Protuberans of the Breast: A Rare Case Report.

Case reports in oncology
2026

High-grade leiomyosarcoma of the common femoral vein masquerading as a femoral artery aneurysm in an elderly patient: A diagnostic challenge.

Radiology case reports
2026

Pharmacokinetics of pazopanib: a review of the determinants, influencing factors and the clinical importance of therapeutic drug monitoring.

The Journal of pharmacy and pharmacology
2026

Update on pediatric soft tissue sarcomas.

Current opinion in pediatrics
2025

Retroperitoneal dedifferentiated liposarcoma with colon infiltration: a case report and literature review.

Frontiers in oncology
2025

Neoadjuvant chemotherapy, DEB-TACE, and 3D-printed prosthesis for primary pelvic pleomorphic undifferentiated sarcoma: a case report.

Frontiers in oncology
2025

A Comprehensive Review of Margin Identification Methods in Soft Tissue Sarcoma.

Current oncology (Toronto, Ont.)
2025

The Surveillance After Extremity Tumor Surgery (SAFETY) Pilot International Multi-Center Randomized Controlled Trial.

Current oncology (Toronto, Ont.)
2025

Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression.

Frontiers in oncology
2026

A 3D bioprinted liposarcoma tumor microenvironment model recapitulates stroma-driven invasion and chemoresistance.

Journal of materials chemistry. B
2025

Th17-like cells and immunosuppressive macrophages infiltrate tertiary lymphoid structures with distinct maturation status in soft-tissue sarcoma.

Cell death &amp; disease
2025

Eribulin and sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review.

Frontiers in oncology
2026

Exploring hospital volume thresholds for improved sarcoma treatment across different age categories in the United States.

Cancer
2025

A Comprehensive Review of Chemotherapy in Localized Soft Tissue Sarcomas: Is the Cat Out of the Bag Yet?

Indian journal of surgical oncology
2025

MRI-based deep learning and radiomics pipeline for myxoid liposarcoma: a feasibility study in a rare sarcoma.

Scientific reports
Ver todos os 4.685 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Sarcoma de tecidos moles.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Sarcoma de tecidos moles

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332.
    Pediatric blood &amp; cancer· 2026· PMID 41840819mais citado
  2. Local Control of Bladder/Prostate Rhabdomyosarcoma: An Expert Consensus Guideline From the International Soft Tissue Sarcoma Consortium (INSTRuCT).
    Pediatric blood &amp; cancer· 2026· PMID 41823170mais citado
  3. VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma.
    International journal of biological sciences· 2026· PMID 41800245mais citado
  4. A Phase 1 Study of Neoadjuvant Cabozantinib in Combination With Radiation Therapy for Sarcomas of the Extremities.
    American journal of clinical oncology· 2026· PMID 41770651mais citado
  5. From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.
    Frontiers in cell and developmental biology· 2026· PMID 41768998mais citado
  6. EXPRESS: Feline tarsal tumors: histologic spectrum, risk factors, and prognostic insights.
    J Feline Med Surg· 2026· PMID 41994862recente
  7. ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival.
    ESMO Rare Cancers· 2026· PMID 41994103recente
  8. Prognostic impact of tumour-vessel proximity in soft tissue sarcoma: Fujiwara classification provides enhanced risk stratification.
    World J Surg Oncol· 2026· PMID 41992231recente
  9. Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.
    Nat Med· 2026· PMID 41991689recente
  10. Liposomal Versus Conventional Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas: Observational Multi-Institutional Cohort of 8.5-Year Experience.
    JCO Oncol Pract· 2026· PMID 41990299recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:3394(Orphanet)
  2. MONDO:0018078(MONDO)
  3. GARD:4898(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q720020(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Sarcoma de tecidos moles
Compêndio · Raras BR

Sarcoma de tecidos moles

ORPHA:3394 · MONDO:0018078
Prevalência
1-5 / 10 000
Ensaios
16 ativos
Prevalência
30.0 (Europe)
MedGen
UMLS
C0334492
Repurposing
1 candidato
pazopanibKIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades